관련근거
1)Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition (2023)
2)Current Medical Diagnosis and Treatment (2023)
3)Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2022 Recommendations of the International Antiviral Society？USA Panel (2022)
4)EACS(European AIDS Clinical Society) Guidelines (2023)
5)C.Orkin et al. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection The NEW ENGLAND JOURNAL of MEDICINE 2020;382;pages 1124-1135.
6)S. Swindells et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression The NEW ENGLAND JOURNAL of MEDICINE 2020;382;pages 1112-1123.
7)S. Swindells et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial Lancet HIV 2023;10;pages e566-577.
8)Edgar T Overon et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study The Lancet 2020;396;pages 1994-2005.
9)Hans Jaeger et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Lancet HIV 2021;8;pages 679-689.
10)Edgar T. Overton et al. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study Clinical Infectious Diseases 2023;76;pages 1646-1654.
11)대한감염학회(대감학 24-132, 2024.7.25.)
12)대한에이즈학회(대에학 2024-20, 2024.7.26.)
13)대한향균요법학회(대항균 24-045, 2024.7.24.)
14)NICE (2022.1.5.)
15)SMC (2021.9.10.)
16)PBAC (2022.3.4.)
17)CADTH (2020.9.9.)